NBIS, CSCO, SLS Stocks Hit 52-Week Highs Today: What's Behind The Surge?
Nebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) hit 52-week highs. Nebius reported Q1 revenue of $399M, up 684% YoY, and raised 2026 ARR guidance to $7B-$9B, plus access to up to 1.2 GW power for an AI facility. Cisco raised AI infrastructure order forecast to about $9B and reported Q3 revenue of $15.8B. SLS said its Phase 3 REGAL AML study is nearing a final event threshold and reported $107M+ cash.
How this was made
The 30-second read
Why it matters
NBIS and CSCO received guidance and demand visibility upgrades tied to AI infrastructure buildout, while SLS moved closer to a pivotal Phase 3 readout threshold. These are the types of catalysts that can change near-term expectations and trading ranges.
Market read
The article provides same-day, company-specific catalysts (guidance/clinical progress) that can justify momentum trading and tighter risk controls around execution and timing.
What to watch
The article mentions Cisco restructuring (about 4,000 job cuts) and trial timing uncertainty for SLS; traders may need to monitor margin/cost impacts and whether the “final event threshold” timing compresses or drifts.
Background
The piece frames three separate 52-week-high moves as being driven by tangible AI infrastructure progress (NBIS, CSCO) and late-stage oncology trial advancement (SLS).
Ticker impact
Nebius reported Q1 revenue of $399M (+684% YoY) and raised 2026 ARR guidance to $7B-$9B, driving a >15% surge to a 52-week high.
Bullish bias for follow-through, with volatility tied to whether hyperscaler demand and power-capacity execution match the raised ARR outlook.
The article cites specific, time-stamped financial metrics (Q1 revenue, ARR outlook) and a concrete capacity access figure (up to 1.2 GW), which are direct catalysts for repricing.
Cisco raised its AI-related infrastructure orders forecast to about $9B for the fiscal year from $5B, alongside Q3 results that beat consensus.
Likely continued upside bias while traders digest the larger AI orders outlook, tempered by execution risk and restructuring costs.
The article provides a clear forecast step-up ($5B to ~$9B) plus beat metrics (Q3 revenue and EPS), both of which typically drive immediate repricing.
Sellas Life Sciences advanced its Phase 3 REGAL leukemia study, nearing the final event threshold for a key AML data readout, and shares jumped 25%.
Near-term bullish skew into the next trial milestone, with sharp pullbacks possible if timing slips or data quality disappoints.
The article highlights trial-stage advancement (Phase 3 nearing final event threshold) and concurrent cash runway, but it does not provide the actual readout results.
Market effects
Reinforces investor appetite for AI infrastructure enablers (power/capacity and networking) and for biotech with late-stage AML catalysts.
Primarily US-listed large-cap tech and US-listed biotech sentiment; limited direct regional spillover implied.
Hyperscaler AI buildout demand and global AI infrastructure capex expectations are the common macro driver across the tech names.
Counterpoint
52-week-high breakouts can overshoot on retail-driven momentum; execution risk (power delivery for NBIS, AI order conversion for CSCO, trial timing for SLS) could cap follow-through.
Key entities
- companyNebius Group
Reported Q1 revenue surge and raised 2026 ARR outlook; also secured access to up to 1.2 GW of power capacity for an AI facility.
- companyCisco Systems
Raised AI-related infrastructure orders forecast to about $9B for the fiscal year and reported Q3 revenue and EPS beats; also outlined restructuring.
- companySellas Life Sciences Group
Updated on Phase 3 REGAL study progress toward a key AML data readout threshold and began treating patients in a Phase 2 trial.
